Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23289332 | 0.97 | TLR8 (0.40) | TLR8TLR7FGFR1ACKR3CA12 | |
| SCHEMBL23289347 | 0.88 | TLR8 (0.49) | TLR8TLR7 | |
| SCHEMBL23340000 | 0.87 | TLR8 (0.35) | TLR8TLR7 | |
| SCHEMBL23339879 | 0.87 | TLR8 (0.36) | TLR8TLR7 | |
| SCHEMBL23289496 | 0.87 | TLR8 (0.35) | TLR8TLR7 | |
| SCHEMBL23273953 | 0.86 | TLR8 (0.38) | TLR8TLR7 | |
| SCHEMBL23273929 | 0.84 | TLR8 (0.37) | TLR8TLR7 | |
| SCHEMBL23274081 | 0.84 | TLR8 (0.36) | TLR8TLR7 | |
| SCHEMBL23289487 | 0.83 | TLR8 (0.34) | TLR8TLR7 | |
| SCHEMBL23289445 | 0.83 | TLR8 (0.38) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210128744-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2021081402-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081407-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | ICOS, CYP3A5, TPH1 | TLR8 3844/4885TLR7 2077/4885PARP1 1636/4885 |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | ICOS, CYP3A5, TPH1 | TLR8 3844/4885TLR7 2077/4885PARP1 1636/4885 |
| US-20210128744-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | ICOS, CYP3A5, TPH1 | TLR8 3844/4885TLR7 2077/4885PARP1 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.